← Leaderboards
Daniel A Barocas
Vanderbilt University
$3,581,756
Attributed
$3,581,756
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $725.3K · FY2013–24$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,581,756 · 4
By mechanism
R01$3,149,983 · 1
R03$307,320 · 2
P30$124,453 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- David O. Francis$3,456,343
- William M Grady$22,313,396
- Pierre P Massion$18,568,000
- Dennis E Hallahan$13,109,924
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCohortCohort StudiesDiagnosisPopulation BasedComparative EffectivenessProviderToxic EffectElderlyShared Decision MakingRaceSex FunctioningPublicationsUrinaryRadiationOperative Surgical ProceduresMalignant Neoplasm Of ProstateMedicalResearch PersonnelComorbidityDisorder RiskData ReportingData CollectionEnrollment
Grant awards (10)
Cancer Health Outcomes and Control Research Program$124,453
P30 · FY2024 · CA · contact PI
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer$554,265
R01 · FY2023 · CA · contact PI
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer$606,437
R01 · FY2022 · CA · contact PI
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer$628,064
R01 · FY2021 · CA · contact PI
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer$635,948
R01 · FY2020 · CA · contact PI
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer$725,269
R01 · FY2019 · CA · contact PI
Trends in Surveillance for Localized Prostate Cancer and Barriers to its Use$75,660
R03 · FY2014 · CA · contact PI
The Quality of Care in Evaluating Patients Suspected of Having Bladder Cancer$75,660
R03 · FY2014 · CA · contact PI
Trends in Surveillance for Localized Prostate Cancer and Barriers to its Use$78,000
R03 · FY2013 · CA · contact PI
The Quality of Care in Evaluating Patients Suspected of Having Bladder Cancer$78,000
R03 · FY2013 · CA · contact PI